A recent phase 1b study has evaluated the efficacy of AK117, an anti-CD47 agent, in combination with AZA as a frontline treatment for AML patients and has demonstrated a CR and CR/CRi rate of 45% and 55%, respectively [77]. Here, CD47 is linked to acute myeloid leukemia.